Industry Reacts to FDA Draft Guidance on Injectable Products Inspection

Pharmaceutical companies and the International Society for Pharmaceutical Engineering want the FDA to align visible particle classifications and inspections with USP.

Morgan SmithContributing Editor, ProFood World

Mar 1st, 2022

The FDA draft guidance for manufacturers on developing and implementing particle control programs for injectable products, which was issued following numerous recalls due the particulate contamination of injectable products and the agency’s concern for patient safety, has prompted quick reactions from several pharmaceutical companies and industry groups.

A key point of concern is how the guidance defines inherent, intrinsic, and extrinsic particulates, in that the definition doesn’t completely match with that of the US Pharmacopoeia (USP).

According to a recent article published by the Regulatory Affairs Professionals Society, drug makers and pharmaceutical industry groups, including the International Society for Pharmaceutical Engineering (ISPE), Boehringer Ingelheim, and Novartis, want the FDA to align its classification categories for visible particles with (USP) Chapter 1790, “General Chapter Visible Particulates in Injections,” which defines particle categories and describes inspection procedures used to demonstrate injectable products are essentially free from particulates.

Food and Drug Administration

FDA Holding Webinar on Animal Drug Manufacturing System eSubmitter Tool

The session will provide information about new enhancements to the system used to support the creation of electronic, secure submissions to the FDA’s Center for Veterinary Medicine for review.

2022 Pdafda Linkedin

2022 PDA/FDA Joint Regulatory Conference

Hosted by the Parenteral Drug Association (PDA), the conference takes place Sep 12 - Sep 14, 2022 in Washington D.C.

FDA Flexibilities to Yield Millions of Cans of Additional Infant Formula

In the coming months, the FDA will be able to greatly increase the supply of formula, including Abbott EleCare, available to U.S. consumers through international and domestic manufacturing facilities.

FDA Releases White Paper on Quality Management Maturity

The new white paper discusses developing a framework to evaluate the QMM of pharmaceutical manufacturing sites and the benefits of a rating system.

At the[PACK]out, presenting 'Wicked Stability: Predicting the Aging Degradation of Materials' were speakers (from left): Dan Burgess, Henk Blom, and Rod Patch w/ Moderator Seema Momin.

KiiP Tackles Wicked Problems in Package Material Stability

What began as a chat over coffee has led to work on a hypothesis and a white paper with far-reaching potential in saving time and resources in medical device packaging stability testing. Efforts were presented at the[PACK]out's inaugural event in Austin.

FDA Permits Marketing for Test to Improve Diagnosis of Alzheimer’s Disease

The Lumipulse test is intended to measure the ratio of β-amyloid 1-42 and β-amyloid 1-40 concentrations found in human cerebral spinal fluid.

the[PACK]out: Supply Chain - Navigating Disruptions

EXPERIENCE the[PACK]out: Created for industry professionals, by industry professionals.

FDA Issues New Guidance to Increase Racial and Ethnic Diversity in Clinical Trials

The agency’s focus on inclusion in trials for all medical products aligns with Biden Administration’s Cancer Moonshot goal of addressing inequities and beyond.

Cybersecurity in Medical Devices: FDA Announces New Draft Guidance

The new guidance deals with quality system considerations and the content of premarket submissions for members of the medical device industry, as well as Food and Drug Administration staff.

Speakers from left at TempPack: Mark Maurice, Sensitech; Eric Silberstein, eBiotech Consulting, LLC; Bryan Cardis, Eli Lilly and Company; Arif Rahman, MaxQ Research LLC

10 Temperature Monitor Qualification Considerations

From the 2022 ISTA Forum TempPack: Panelists discussed the latest on temperature recording device (TRD) qualification, including dry ice and LCD screens, probes that disconnect, and what to consider before selecting a shipper integrated with a TRD.

FDA Recommends Use of Duodenoscopes With Innovative Designs to Enhance Safety

The agency is providing new information supporting the transition to fully disposable duodenoscopes and those with disposable components, as well as new information on completed post-market surveillance studies.

Solution for Expiry Labels, DtP, and Study Timelines Due to EU 536/2014 Clinical Trials Regulation

The new regulation improves many aspects of clinical preparation and activation but brings certain new challenges for sponsors.

Heuft Spotter Ii Phs

Full Vial Inspection: Simply Complete!

Unit carries out optical and radiometric inspection and volumetric determination of O2 content in the headspace

Getty Images 1161368565

Future for Pharmaceutical Manufacturers Includes More Digitized Data Collection

While automation is driving physical changes to pharmaceutical production and packaging processes, another significant shift is occurring in the accumulation and use of data.

Regulation EU No 536/2014 on clinical trials will come many changes that will impact study startup processes and timelines, expiry labeling on primary and secondary packaging, and study administration methods such as direct-to-patient.

Part 1: Manage Challenges from the EU 536/2014 Clinical Trials Regulation

Plan ahead for study startup timelines, expiry labeling on primary packaging solutions, and study administration methods.

Pw 7643 Web Cargo

Tips for Exporting Goods in 2022

Live from Natural Products Expo West: An international trade expert discusses why you need to know your buyers, what you can ship to a sanctioned country, insurance for sea cargo, and more.

FDA Issues Voluntary Recalls Final Guidance

The guidance will help companies prepare to quickly and effectively remove violative products from the market, as the agency urges companies to be “recall ready” to protect public health.

Industry Reacts to FDA Draft Guidance on Injectable Products Inspection

Pharmaceutical companies and the International Society for Pharmaceutical Engineering want the FDA to align visible particle classifications and inspections with USP.

FDA Proposes Rule to Amend Medical Device CGMP Requirements

The proposed amendments to the CGMP requirements of the Quality System (QS) Regulation will align them more closely with the international consensus standard for devices.

Fda Chief Robert Califf

New FDA Chief Confirmed by Senate

Dr. Robert Califf narrowly secures position again on a 50-46 vote, despite concerns over his pharmaceutical industry ties.

More in Regulatory

FDA Proposes Rule for Wholesale Drug Distributors, Third-party Logistics Providers

If passed, the rule would allow only those licensed according to the proposed national standards to engage in transactions related to the sale and distribution of certain prescription drugs with other members of the supply chain.

FDA Publishes Draft Guidance on Reporting Certain Medical Device Shortages

The new guidance helps clarify how the agency interprets 506J notification requirements, including when and who should submit a notification and the information that should be included.

Safety in Aseptic Filling

FDA provides insight into common pitfalls found during inspections along with possible solutions.

FDA Releases Medical Devices Draft Guidance for Review

“The Transition Plan for Medical Devices Issued Emergency Use Authorizations During the Coronavirus Disease 2019 Public Health Emergency” guidance is now available for review.

Aseptic processing is one of the highest risk pharmaceutical operations, and thus requires a high level of control.

Pitfalls to Avoid in FDA Aseptic Manufacturing Inspections

From personnel to facility design to process, FDA policy advisor provides an outline of what facilities can improve on.

Serialization Master Data 60a571e0dae99

Counting Down the Top 10 Articles of 2021 - #1: Serialization 101

Join us as we look back at the most-read Healthcare Packaging stories of 2021. At #1, we’re going back to basics with an introductory look at serialization, required by pharma and medical device regulations to defend against counterfeiting.

Getty Images 1208358564 6073d57fe5816

Counting Down the Top 10 Articles of 2021 - #4: Data and AI Accelerate Digital Transformation

Join us as we look back at the most-read Healthcare Packaging stories of 2021. At #4, we cover the growing need for pharma manufacturing facilities to become digitalized to improve productivity and make the most of the ‘digitally native’ workforce.

FDA Discusses Nov. 2023 DSCSA Future State

At the HDA Traceability Online Seminar (Nov. 1-3, 2021), FDA’s Connie Jung, RPh, talked about how DSCSA continues to transform the pharmaceutical supply chain to preserve drug safety and security.

For product traceability, outbound scanning alone is expected to increase labor by a minimum of 12 to 15% based on recent time studies, per Cardinal Health.

Will Labor Requirements Increase in Meeting DSCSA Milestones?

With many companies either facing or concerned about labor shortages in manufacturing, an expert from Cardinal Health notes that outbound scanning alone may require a 12 to 15% increase in headcount in their operations.

Companies are adopting robotics and biometrics initiatives in drug product manufacturing and modern, robust aseptic processing technologies that afford tangible safety benefits to sterile products.

Applying Modern Technology to Pharmaceutical Production Facilities

Robotics, biometrics, and isolator technology are proving cleaner, faster, and safer than traditional manual methods.

Hp 107536 Surgical Tools Copy png 2

EU Regulators, Recycling, and Healthcare Plastics

Packaging suppliers speak about the openness of regulators to understand the slower nature of life science manufacturers in adopting more sustainable packaging.

Screen Shot 2021 11 01 At 7 04 22 Am

HDA Foundation Survey Reveals Uneven Progress on Rx Product Serialization

With 2023 DSCSA requirements around the corner, findings reveal aggregation has slowed. Now in its sixth year, this survey, released as part of HDA’s Traceability Online Seminar (November 1–3), assesses industry abilities to meet DSCSA requirements.